Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
POP90155
CIHR - Canada
PubMed
31678518
DOI
10.1016/j.bbalip.2019.158538
PII: S1388-1981(19)30189-1
Knihovny.cz E-resources
- Keywords
- CFTR, Cystic fibrosis, Mucins, PUFAs,
- MeSH
- Administration, Oral MeSH
- Cell Line MeSH
- Cystic Fibrosis complications genetics pathology MeSH
- Fenretinide administration & dosage MeSH
- Phospholipids metabolism MeSH
- Mucus metabolism MeSH
- Rats MeSH
- Arachidonic Acid metabolism MeSH
- Docosahexaenoic Acids metabolism MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Mucin 5AC metabolism MeSH
- Mucin-5B metabolism MeSH
- Mice, Inbred CFTR MeSH
- Mice MeSH
- Lung drug effects metabolism pathology MeSH
- Pneumonia microbiology pathology prevention & control MeSH
- Pseudomonas Infections microbiology pathology prevention & control MeSH
- Pseudomonas aeruginosa pathogenicity MeSH
- Respiratory Mucosa cytology metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fenretinide MeSH
- Phospholipids MeSH
- Arachidonic Acid MeSH
- Docosahexaenoic Acids MeSH
- Muc5ac protein, mouse MeSH Browser
- Muc5b protein, mouse MeSH Browser
- Mucin 5AC MeSH
- Mucin-5B MeSH
Cystic fibrosis (CF) is the most common genetic disease in Caucasians. CF is manifested by abnormal accumulation of mucus in the lungs, which serves as fertile ground for the growth of microorganisms leading to recurrent infections and ultimately, lung failure. Mucus in CF patients consists of DNA from dead neutrophils as well as mucins produced by goblet cells. MUC5AC mucin leads to pathological plugging of the airways whereas MUC5B has a protective role against bacterial infection. Therefore, decreasing the level of MUC5AC while maintaining MUC5B intact would in principle be a desirable mucoregulatory treatment outcome. Fenretinide prevented the lipopolysaccharide-induced increase of MUC5AC gene expression, without affecting the level of MUC5B, in a lung goblet cell line. Additionally, fenretinide treatment reversed the pro-inflammatory imbalance of fatty acids by increasing docosahexaenoic acid and decreasing the levels of arachidonic acid in a lung epithelial cell line and primary leukocytes derived from CF patients. Furthermore, for the first time we also demonstrate the effect of fenretinide on multiple unsaturated fatty acids, as well as differential effects on the levels of long- compared to very-long-chain saturated fatty acids which are important substrates of complex phospholipids. Finally, we demonstrate that pre-treating mice with fenretinide in a chronic model of P. aeruginosa lung infection efficiently decreases the accumulation of mucus. These findings suggest that fenretinide may offer a new approach to therapeutic modulation of pathological mucus production in CF.
References provided by Crossref.org
The role of essential fatty acids in cystic fibrosis and normalizing effect of fenretinide
